Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KER-050/elritercept in myelofibrosis with anemia
2023-507468-38-00Phase 2Authorised
- Sponsor
- Takeda
- Start
- Sep 2024
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, open-label trial of elritercept and ruxolitinib in myelofibrosis (MF) (4 arms), sponsored by Takeda. Planned start Sep 2024; status: authorised.
02
Drugs
elriterceptruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2023-507468-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507468-38-00.